215
Participants
Start Date
September 13, 2021
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
ZYN002 - transdermal gel
Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
Placebo
"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
Westmead Children's Hospital, Sydney
Genetics Clinics Australia, Melbourne
Lady Cilento Children's Hospital - South Brisbane, Brisbane
Health New Zealand - Te Whatu Ora - Wellington Hospital, Newtown
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics, New York
Penn State Hershey Medical Center, Hershey
Children's National Medical center, Washington D.C.
Kennedy Krieger Institute, Baltimore
Greenwood Genetic Center, Greenville
Rare Disease Research, Atlanta
University of Miami, Miami
University of Mississippi, Jackson
University of Minnesota Fragile X Clinic (Voyager Clinic), Minneapolis
Rush University Medical Center, Chicago
Central States Research, Tulsa
Primary Children's Hospital, Salt Lake City
Phoenix Children's Hospital, Phoenix
Science 37, Culver City
Amnova Clinical Research, LLC, Irvine
Thompson Autism Center CHOC, Orange
UC Davis Health System, MIND Institute, Sacramento
Boston Children's Hospital, Boston
Wellcome HRB Clinical Research Facility, Dublin
University of Edinburgh, Edinburgh
Leicester Clinical Research, Leicester
King's College, London
Manchester University NHS Foundation Trust, Manchester
Zynerba Pharmaceuticals, Inc.
INDUSTRY